4CPS-144 Establishment of a pharmaceutical standardised interview concerning biosimilars of infliximab in the daycare clinic of a gastroenterology department for patients affected by inflammatory bowel disease

BackgroundAnti-TNF monoclonal antibodies such as infliximab effectively treat inflammatory bowel disease (IBD). Currently they are recommended after failure or contraindication of corticosteroid/immunosuppressive therapy. The use of infliximab’s biosimilars is an important question due to health cos...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of hospital pharmacy. Science and practice 2019-03, Vol.26 (Suppl 1), p.A136-A136
Hauptverfasser:	Coget, E, Laffont-Lozes, P, Velasco Gonzalvo, V, Huc, D, Pineton de Chambrun, G, Altwegg, R, Blanc, P, Pageaux, GP, Rosant, D, Breuker, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Economic analysis Gastroenterology Immunotherapy Inflammatory bowel disease Monoclonal antibodies Patients Pharmaceuticals TNF inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!